Treating Iron Deficiency in Patients with HFrEF: A Review of the Recent Data for IV Iron Replacement Therapy

Treating Iron Deficiency in Patients with HFrEF: A Review of the Recent Data for IV Iron Replacement Therapy

Treating Iron Deficiency in Patients with HFrEF: A Review of the Recent Data for IV Iron Replacement Therapy
RestartResume

How can clinical trial design impact outcomes? Our experts have the latest evidence on IV iron in the setting of iron deficiency in heart failure.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Javed Butler, MD, MBA, MPH
    President, Baylor Scott and White Research Institute
    Dallas, TX
    Distinguished Professor of Medicine, University of Mississippi Medical Center
    Jackson, MS, USA

    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Faculty:
    Stefan D. Anker, MD, PhD
    Division of Cardiology & Metabolism: Heart Failure, Cachexia and Sarcopenia
    Department of Cardiology & BCRT
    Berlin, Germany

    Consulting Fees: AstraZeneca, Bayer, Boehringer Ingelheim, Brahms, Novartis, Servier, Vifor Pharma

    Robert J. Mentz, MD, FACC, FAHA, FHFSA
    Associate Professor
    Chief, Heart Failure Section
    Associate Program Director, Duke Cardiovascular Disease Fellowship
    Durham, NC, USA

    Consulting Fees: Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novartis, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor Pharma, Windtree Therapeutics, Zoll
    Contracted Research: American Regent, Bayer, Merck, Novartis

    Piotr Ponikowski, MD, PHD, FESC, FHFA
    Medical University, Centre for Heart Disease
    Clinical Military Hospital
    Wroclaw, Poland

    Consulting Fees: Bayer, Boehringer Ingelheim, Novartis, Servier, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the most recent efficacy and safety data of IV iron replacement therapy in patients with heart failure (HF)
    • Evaluate data from recent clinical trials on the impact of IV iron replacement in terms of symptoms and QoL
    • Discuss similarities and differences of recent IV iron clinical trials and their potential impact on the treatment landscape for patients with HF
    • Discuss the benefits of IV iron replacement therapy and the importance of treating HF patients symptomatically to improve QoL 
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Podcast PLUS activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free